Citius Oncology, Inc. (CTOR)
0.8458
+0.05
(+6.77%)
USD |
NASDAQ |
Sep 04, 16:00
0.8458
0.00 (0.00%)
After-Hours: 17:00
Citius Oncology Net Income (Quarterly) : -8.924M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.924M |
| March 31, 2026 | -26.61M |
| December 31, 2025 | -5.534M |
| September 30, 2025 | -4.997M |
| June 30, 2025 | -5.37M |
| March 31, 2025 | -7.736M |
| December 31, 2024 | -6.659M |
| September 30, 2024 | |
| June 30, 2024 | 0.2525M |
| March 31, 2024 | 0.4898M |
| December 31, 2023 | 1.033M |
| Date | Value |
|---|---|
| September 30, 2023 | 0.1579M |
| June 30, 2023 | 0.6163M |
| March 31, 2023 | 0.6117M |
| December 31, 2022 | 0.3808M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| January 31, 2022 | |
| October 31, 2021 | |
| July 31, 2021 | |
| April 30, 2021 | -0.0094M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Citius Pharmaceuticals, Inc. | -11.92M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.494M |
| Total Expenses (Quarterly) | 10.42M |
| EPS Diluted (Quarterly) | -0.0827 |
| Enterprise Value | 77.43M |
| Gross Profit Margin (Quarterly) | -48.09% |
| Profit Margin (Quarterly) | -597.4% |
| Earnings Yield | -56.01% |
| Normalized Earnings Yield | -56.01 |